MS Drug Denied by Insurance? Ocrevus, Kesimpta, Tysabri, Gilenya Appeal Guide

Multiple sclerosis disease-modifying therapies (DMTs) are among the most expensive drugs in insurance formularies — and among the most commonly denied. From first-line interferons to high-efficacy agents like Ocrevus, Tysabri, and Kesimpta, every category of MS treatment faces Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization scrutiny. Here's how to fight back.

The MS Treatment Landscape: Why Insurers Deny

MS DMTs range from $30,000 to $100,000+ per year. Insurers use several strategies to limit access:

1. Step therapy: Require less effective (and cheaper) first-line DMTs before approving high-efficacy agents
2. Insufficient diagnosis documentation: Requiring specific MRI criteria (McDonald criteria) or relapse documentation before approving any DMT
3. Non-medical switching: Forcing biosimilar or competing product substitutions
4. "Not medically necessary for stable patients": Denying DMT continuation for patients who are doing well — incorrectly, because DMT efficacy depends on continuous use
5. Specific product exclusions: Formulary placement that excludes specific DMTs

Key Drugs and Appeal Arguments by Category

Ocrevus (Ocrelizumab) — Anti-CD20 B-cell Depletion

FDA approved: Relapsing MS (2017), Primary Progressive MS (2017, first DMT approved for PPMS)

OPERA I/II trials: Ocrevus reduced annualized relapse rate (ARR) by 46–47% vs. interferon beta-1a (p<0.001). In PPMS (ORATORIO trial): 25% reduction in confirmed disability progression at 12 weeks (p=0.0321).

Step therapy denial: Insurers may require two prior DMT failures before approving Ocrevus. Challenge by:

• Documenting progressive disease characteristics (new T2 lesions, gadolinium-enhancing lesions, relapses) despite existing DMT
• Citing ECTRIMS/ACTRIMS guidelines: Early high-efficacy therapy is increasingly supported for active RRMS
• For PPMS: No alternative DMTs exist — Ocrevus is the only FDA-approved PPMS DMT

Kesimpta (Ofatumumab) — SC Anti-CD20

FDA approved: Relapsing MS (2020). Self-administered subcutaneous injection every 4 weeks after loading.

ASCLEPIOS I/II trials: Kesimpta reduced ARR by 50.5–58.5% vs. teriflunomide. Superior to teriflunomide on all secondary endpoints.

Appeal vs. Ocrevus: If denied Kesimpta in favor of Ocrevus or vice versa, prescriber preference is justified based on route of administration (self-injection vs. infusion), patient preference, or JC virus antibody status.

Tysabri (Natalizumab) — Anti-VLA-4 Integrin

FDA approved: Relapsing MS (2004, restored with REMS 2006). Also approved for Crohn's.

AFFIRM trial: 68% reduction in ARR vs. placebo (p<0.001).

PML risk (REMS): Tysabri requires strict monitoring for progressive multifocal leukoencephalopathy (PML) due to JC virus reactivation. JC virus antibody index determines risk stratification. This is a valid clinical reason your prescriber may prefer Tysabri over other agents — or vice versa.

Gilenya (Fingolimod) — First Oral S1P Modulator

FDA approved: Relapsing MS (2010, first oral DMT). Now available as generic fingolimod.

FREEDOMS trial: 54% reduction in ARR vs. placebo (p<0.001).

Step therapy: Generic fingolimod is now available (2019). If you're on brand Gilenya and insurer is switching you to generic: generic fingolimod is bioequivalent and the switch is generally scientifically appropriate. If you have a documented intolerance to excipients of the generic formulation, document this specifically.

Tecfidera (Dimethyl Fumarate) — Oral DMT

Now available as generic (Vumerity is a related prodrug). Step therapy often requires failing generic DMF first before brand Vumerity. If you've had GI intolerability issues with dimethyl fumarate, Vumerity (diroximel fumarate) has meaningfully fewer GI side effects — document this as clinical justification.

Mavenclad (Cladribine) — Short-Course Oral DMT

Two short treatment courses (year 1 and year 2), then drug-free for years 3–4+. CLARITY trial: 55% reduction in ARR vs. placebo.

High-efficacy agent often denied pending step therapy failures. Key argument: Mavenclad's short-course dosing creates an immune reconstitution effect with durable benefits — delay imposes ongoing MS damage during the waiting period.

Universal Appeal Arguments for MS DMT Denials

1. Disease Activity Documentation

Provide:

• MRI brain and spine (ideally with gadolinium contrast): document new T2 lesions, gadolinium-enhancing lesions, lesion burden
• Relapse history: number of relapses in past 12 months, EDSS scores before/after relapse, duration of recovery
• EDSS (Expanded Disability Status Scale): document current score and trajectory
• MSFC (Multiple Sclerosis Functional Composite): timed walk, 9-hole peg test, PASAT

2. Counter "Step Therapy Required"

• Show the specific failures of prior DMTs: drug name, dose, duration, ARR on drug, breakthrough lesions or relapses
• Argue: "Continued step therapy on less effective agents causes irreversible MRI lesion accumulation and future disability"
• Cite ECTRIMS 2022 recommendations supporting early high-efficacy therapy for highly active RRMS

3. "Stable Patients Don't Need DMT"

Insurers sometimes deny DMT renewal for stable patients. Counter:

• MS stability IS the result of effective DMT — discontinuing creates relapse risk
• Cite the FREEDOMS study: stopping fingolimod caused rebound relapses in some patients
• "Stability on current therapy is evidence the therapy is working, not evidence it is unnecessary"

Patient Assistance Programs

While you appeal:

• Genentech Access Solutions: Ocrevus copay assistance and free drug programs
• Novartis Patient Assistance: Kesimpta savings programs
• Biogen Patient Services: Tysabri, Tecfidera assistance
• MS Lifelines: Multiple MS manufacturer programs

Fight Back With ClaimBack

ClaimBack generates MS DMT appeal letters that cite OPERA, ASCLEPIOS, AFFIRM, FREEDOMS, and CLARITY trial data, ECTRIMS guidelines, and your specific MRI/relapse history.

Start your free MS drug appeal at ClaimBack →

Related Reading

• Step Therapy Override: Your Right to Skip the Insurance Ladder
• What Is Medical Necessity (and How to Prove It)?
• Prior Authorization Denied? Complete Appeal Guide